Key result
The Virtual Assay software enables in silico drug trials in human cardiac models, providing accurate and mechanistic predictions of drug-induced cardiac pro-arrhythmic toxicity.
Why the study?
Predicting drug effects on the heart remains a challenge in drug development due to potential adverse outcomes, and computer modelling offers technology to augment existing animal and clinical methods.
Population
Population of human cardiac models
Comparison
Virtual Assay software for in silico drug trials
Design
In silico modelling and simulation study
Authors
Loading...
May augment preclinical cardiac safety screening; leaves open prospective validation before regulatory or clinical adoption.
The Virtual Assay software provides a user-friendly in silico platform to accurately predict drug-induced cardiac pro-arrhythmic toxicity, augmenting traditional animal and clinical testing.
Passini et al. (2020) studied Drug-induced cardiac pro-arrhythmic toxicity. Virtual Assay software was evaluated on Prediction of drug-induced cardiac pro-arrhythmic toxicity. The Virtual Assay software enables in silico drug trials in human cardiac models, providing accurate and mechanistic predictions of drug-induced cardiac pro-arrhythmic toxicity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: